The Nicotine Climate of Fear: How Institutional Risk-Aversion Is Paralyzing Public Health

The FDA's decision calculus is asymmetric—and the asymmetry is killing people. When the agency authorizes a product that later turns out to cause harm, the consequences are immediate and severe: Congressional hearings, media investigations, career damage, institutional reputational harm. When the agency fails to authorize a product that would have prevented harm, the consequences are diffuse and invisible: smokers continue to smoke, some of them die, and no one attributes their deaths to the FDA's failure to authorize the product that could have helped them quit. **The institutional incentive structure punishes false positives (authorizing a harmful product) and ignores false negatives (failing to authorize a beneficial product). The result is regulatory paralysis—an agency that is systematically biased against action, because action carries risk and inaction does not.**

**The climate of fear is rational from the perspective of the individuals within the agency.** A regulator who approves a vaping product that later turns out to have significant long-term health effects—even if those effects are orders of magnitude smaller than the effects of the smoking the product prevented—will be held personally responsible. Their career will be damaged. They may be called to testify before Congress. Their professional reputation will be permanently associated with a regulatory failure. A regulator who denies the same product—who takes the precautionary route—faces none of these consequences. The smokers who continue to smoke, who develop lung cancer, who die—their deaths are attributed to their own behavior, not to the regulatory decision that limited their access to alternatives. **The asymmetry creates a powerful incentive for regulators to say no—to protect themselves by protecting the public from potential harm, even if the net effect of the protection is to increase actual harm.**

**The precautionary principle—the formal expression of the climate of fear—is not a neutral decision rule.** It demands that the proponents of a new product demonstrate safety before the product is made available, while imposing no equivalent burden on the existing product (cigarettes) to demonstrate that its continued availability is justified. The precautionary principle treats the status quo as the default—as if the status quo were neutral, rather than an environment in which a known lethal product is freely available. **The precautionary principle, as applied to nicotine regulation, is not evidence-based. It is a framework that systematically favors the most harmful products (cigarettes) over less harmful alternatives—because the alternatives must prove their safety, while the cigarettes are assumed to be acceptable because they already exist.**

**The solution requires institutional reform that addresses the incentive asymmetry.** Regulatory agencies need to be evaluated not just on the harms they prevent (the false positives they avoid) but on the harms they allow (the false negatives they permit). The FDA should be required to estimate the public health impact of its regulatory delays—how many smokers continued to smoke, and how many of them died, because the agency took years to authorize products that could have helped them quit. The estimates would be uncertain, model-dependent, and contested—but their existence would change the institutional calculus by making the cost of inaction visible. **The climate of fear persists because the costs of inaction are invisible. Making them visible—quantifying the lives lost to regulatory delay—would change the institutional incentives that sustain the paralysis.**

**💬 Do you think the FDA is too cautious—that the fear of making a mistake is preventing the agency from making decisions that could save lives?** Or is the caution justified, given the uncertainty about long-term effects? And how should we balance the risk of acting against the risk of not acting?